TERAVOLT - Thoracic cancERs international coVid 19 cOLlaboraTion [COVID-19] [UPH]

  • Research type

    Research Study

  • Full title

    International registry on thoracic cancer patients with COVID-19

  • IRAS ID

    283697

  • Contact name

    Paul Shaw

  • Contact email

    paul.shaw@wales.nhs.uk

  • Sponsor organisation

    Fondazione IRCCS "Istituto Nazionale dei Tumori"

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    The World Health Organisation (WHO), declared COVID-19 (a disease induced by the novel coronavirus SARS-CoV-2) on 11 March 2020 a pandemic, meaning a global outbreak of disease.

    Signs and symptoms of COVID-19 include fever, cough and shortness of breath. Some people who get COVID-19 may experience only mild illness. However, the virus can also cause pneumonia, which can be severe. Early information from China, where COVID-19 first started, shows that some people are at higher risk of getting very sick from this illness. This includes older adults and people with serious chronic medical conditions like heart disease, diabetes and lung disease, especially those patients with lung cancer. It is well known that cancer patients are more likely to get infections than healthy people and non-cancer patients.

    This international database registry seeks the real-time collection of pertinent health data of patients with lung cancer who become infected with COVID-19. As part of this project investigators/physicians from around the world will enter data from their patients.

    Clinical data will be extracted from medical records of consecutive patients from 01 January 2020 until the end of the pandemic is declared by the World Health Organisation (WHO).

    Inclusion: The protocol describes the inclusion of any thoracic cancer patient with a COVID-19 diagnosis defined according to the protocol.

    Outcomes: The protocol describes the explorative endpoints to be evaluated. It is hoped that the entry of data will find patterns that can help treat/prevent severe illness or death of future lung cancer patients that become infected with COVID-19.

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    20/HRA/3031

  • Date of REC Opinion

    17 Jul 2020

  • REC opinion

    Further Information Favourable Opinion